Dillon Martinson is a special counsel in the firm’s CFIUS practice. Dillon advises clients on national security matters, specializing in helping clients navigate voluntary and mandatory CFIUS filings. Previously, Dillon served as a senior policy advisor at the US Department of the Treasury where he led over 60 CFIUS reviews and negotiated numerous complex and confidential mitigation agreements between transaction parties and the government. Dillon’s unique perspective provides clients with an in-depth understanding of the CFIUS process and broader government viewpoints on national security.
Cooley advised Cellares, the first integrated development and manufacturing organization dedicated to clinical and industrial-scale cell therapy manufacturing, on its $255 million financing.
Cooley advised ColdQuanta, a global quantum technology company, on its $110 million Series B financing round. The company will use the capital to commercialize its product portfolio to include quantum computing, quantum algorithms and applications, atomic clocks, sensors and components. Partner Mike Nelson led the Cooley team advising ColdQuanta.
CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion
January 10, 2023
Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.
Fernweh to Acquire Controlling Interest in AZZ Infrastructure Solutions Segment
July 23, 2022
Cooley advised affiliates of Fernweh Group on its definitive agreement with AZZ. Lawyers Ian Nussbaum and Bill Roegge led the Cooley team advising Fernweh.
